Page 28 - Read Online

Cheng et al. Cancer Drug Resist. 2025;8:46 Page 21 of 28

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by the National Natural Science Foundation of China (81503010) and the Natural
Science Foundation of Shaanxi Province (2021SF-300) of China. Yoon J acknowledges support from the
National Research Foundation of Korea (NRF), funded by the Korean government (MSIT) (Nos.
2022R1A2C3005420 and 2022M3E5F3080873). The Basic Science Research Program through the National
Research Foundation of Korea (NRF) funded by the Ministry of Education supported this research
(2022M3H4A1A03067401). This research was also supported by a grant by the Korea Health Technology
R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of
Health & Welfare, Republic of Korea (RS-2023-00265981) and a Korea Basic Science Institute (National
Research Facilities and Equipment Center) grant funded by the Ministry of Education supported this
research (2023R1A6C103A026).

Conflicts of interest
Yoon J is one of the Guest Editors of the Special Issue Topic: Advancements in Precision Medicine for
Overcoming Cancer Drug Resistance. The other authors declare that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2025.

REFERENCES
1. Yang M, Zhang C, Wang R, Wu X, Li H, Yoon J. Cancer immunotherapy elicited by immunogenic cell death based on smart
nanomaterials. Small Methods. 2023;7:2201381. DOI PubMed
2. Petiti J, Arpinati L, Menga A, Carrà G. The influence of fatty acid metabolism on T cell function in lung cancer. FEBS J.
2025;292:3596-615. DOI PubMed
3. Feng Y, Tang Q, Wang B, et al. Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. J
Nanobiotechnol. 2024;22:3005. DOI PubMed PMC
4. Sadeghi M, Moslehi A, Kheiry H, et al. The sensitivity of acute myeloid leukemia cells to cytarabine is increased by suppressing the
expression of Heme oxygenase-1 and hypoxia-inducible factor 1-alpha. Cancer Cell Int. 2024;24:3393. DOI PubMed PMC
5. Song CW, Kim H, Kim M, et al. Role of HIF-1α in the responses of tumors to radiotherapy and chemotherapy. Cancer Res Treat.
2025;57:1-10. DOI PubMed PMC
6. Qi H, Ma X, Ma Y, Jia L, Liu K, Wang H. Mechanisms of HIF1A-mediated immune evasion in gastric cancer and the impact on therapy
resistance. Cell Biol Toxicol. 2024;40:9917. DOI PubMed PMC
7. Xun Z, Zhou H, Shen M, et al. Identification of hypoxia-ALCAM high macrophage- exhausted T cell axis in tumor microenvironment
remodeling for immunotherapy resistance. Adv Sci. 2024;11:e2309885. DOI PubMed PMC
8. Lu Y, Sun Q, Guan Q, et al. The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma. J Hepatol.
2023;79:1172-84. DOI PubMed
9. Shi S, Ou X, Liu C, Wen H, Ke J. Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment.
Front Immunol. 2025;16:1549276. DOI PubMed PMC
10. Rodríguez F, Caruana P, De la Fuente N, et al. Nano-based approved pharmaceuticals for cancer treatment: present and future
challenges. Biomolecules. 2022;12:784. DOI PubMed PMC
11. Meng X, Shen Y, Zhao H, Lu X, Wang Z, Zhao Y. Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review. J
Nanobiotechnol. 2024;22:2859. DOI PubMed PMC
12. Zhang J, Zhang A, Guo Y, et al. Nanoparticle-mediated cuproptosis and photodynamic synergistic strategy: a novel horizon for cancer
therapy. Cancer Med. 2025;14:e70599. DOI PubMed PMC
21